Unlike cervical cancer, endometrial cancer often presents with symptoms at an early stage, per the Mayo Clinic, resulting in ...

Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

Loni Anderson’s cause of death has been confirmed as a rare and aggressive form of uterine cancer that occurs in just 6 out ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...

An international study led by MHH compares genomic data from national biobanks worldwide and identifies new risk factors in DNA that promote tumor development in the lining of the uterus.

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast ...

Endometrial cancer usually returns within three years after treatment. Most of the studies that looked at recurrence rates lasted less than five years, so it's hard to know exactly how many ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

Endometrial cancer is a disease in which cancerous cells form in the tissues of the endometrium, which is part of the uterus. Huntsman Cancer Institute’s Gynecologic Cancers Program provides ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can ...

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...